Integrated Proteins Intrinsic Value
Integrated Proteins (INTEGFD) median intrinsic value is ₹6.40 from 7 valuation models (range ₹4–₹11), vs current price ₹13.55 — -52.8% downside (Trading Above Calculated Value), margin of safety -100.0%. For current market price and key ratios, visit Integrated Proteins stock price NSE.
INTEGFD Valuation Methods Summary — DCF, Graham Number & P/E
Integrated Proteins intrinsic value across 7 models vs current price ₹13.55 — upside/downside and value range per method. Check Integrated Proteins market worth to track the company's total market size over time.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹4.80 | ₹3.84 - ₹5.76 | -64.6% | EPS: ₹0.40, Sector P/E: 12x |
| Book Value Method | asset | ₹11.05 | ₹9.95 - ₹12.16 | -18.5% | Book Value/Share: ₹11.05, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹8.84 | ₹7.96 - ₹9.72 | -34.8% | Revenue/Share: ₹11.05, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹5.42 | ₹4.88 - ₹5.96 | -60.0% | EBITDA: ₹1.00Cr, EV/EBITDA: 6x |
| PEG Ratio Method | growth | ₹6.40 | ₹5.76 - ₹7.04 | -52.8% | EPS Growth: 20.0%, Fair P/E: 16.0x |
| Growth Adjusted P/E | growth | ₹4.07 | ₹3.66 - ₹4.48 | -70.0% | Revenue Growth: 15.0%, Adj P/E: 8.6x |
| Graham Defensive Method | conservative | ₹9.97 | ₹8.97 - ₹10.97 | -26.4% | EPS: ₹0.40, BVPS: ₹11.05 |
INTEGFD Intrinsic Value vs Market Price — All Valuation Models
Integrated Proteins fair value range ₹4–₹11 vs current market price ₹13.55 across 7 valuation models. See INTEGFD book value comparison to compare market price against book value per share.
INTEGFD Intrinsic Value Analysis — Undervalued or Overvalued?
Integrated Proteins median intrinsic value ₹6.40, current price ₹13.55 — Trading Above Calculated Value by 52.8%, margin of safety -100.0%.
What is the intrinsic value of INTEGFD?
Based on our comprehensive analysis using 7 different valuation methods, the estimated intrinsic value of Integrated Proteins (INTEGFD) is ₹6.40 (median value). With the current market price of ₹13.55, this represents a -52.8% variance from our estimated fair value.
The valuation range spans from ₹4.07 to ₹11.05, indicating ₹4.07 - ₹11.05.
Is INTEGFD undervalued or overvalued?
Based on our multi-method analysis, Integrated Proteins (INTEGFD) appears to be trading above calculated value by approximately 52.8%.
INTEGFD Financial Health — Key Ratios vs Industry Benchmarks
Integrated Proteins financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 4.8% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 3.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.00x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
INTEGFD Cash Flow Quality — Operating & Free Cash Flow
Integrated Proteins operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-24 Cr | ₹-24 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |